Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

Joesph Mikhael, Hong Chang

Research output: Contribution to journalArticle

3 Scopus citations


The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Original languageEnglish (US)
Pages (from-to)82-86
Number of pages5
JournalLetters in Drug Design and Discovery
Issue number2
StatePublished - Mar 1 2007



  • Bortezomib
  • Cancer
  • Clinical trial
  • Multiple myeloma
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this